HOME >> MEDICINE >> NEWS
Better survival seen for early breast cancer patients switched from tamoxifen to Aromasin

ATLANTA, June 3, 2006 New data from the Intergroup Exemestane Study (IES) showed for the first time today that hormone sensitive postmenopausal early breast cancer patients who switched to Aromasin after 2 to 3 years of tamoxifen were 17% more likely to be alive and were 25% less likely to have their cancer return than patients who continued on tamoxifen for a full 5 years of therapy.

"Exemestane is the only anti-hormonal therapy that has been shown to demonstrate improved overall survival over tamoxifen alone," said Lead Investigator Professor Charles Coombes, director of cancer medicine, Imperial College, London. These significant survival benefits were seen in patients who are considered hormone sensitive, which represents 97% of the study population. Although not statistically significant in the intent to treat population, 15% of patients taking Aromasin were more likely to be alive versus those that continued on tamoxifen. These new findings were based on nearly 5 years of follow-up after randomization in the IES trial. IES was a large randomized double blind multinational trial of postmenopausal women with early breast cancer which was designed to compare the clinical benefits of switching 2352 patients to Aromasin after 2 to 3 years of tamoxifen versus continuing 2372 patients on tamoxifen for a full 5 years of therapy. The 5 year follow-up time includes a period of observation lasting over 2 years after completion of all treatment.

Earlier results of the IES trial, which led to US FDA and European regulatory approvals of Aromasin for treatment of early breast cancer, found that postmenopausal hormone receptor positive patients, which represented 85% of all patients in the trial, who switched to Aromasin reduced their risk of breast cancer recurring by 35% versus patients who stayed on tamoxifen for 5 years. At the earlier time point, a difference in overall survival had not been seen.

Breast cancer is one of the most comm
'"/>


3-Jun-2006


Page: 1 2 3

Related medicine news :

1. Better mobility keeps seniors healthier
2. Better insight into brain anatomical structures
3. Better health twice as likely for nonsmokers who live and work with smoking restrictions
4. Better designed roadway intersections can boost older drivers performance
5. Better strategies for osteoporosis prevention and therapy
6. Better review of new technology is needed to reduce health costs
7. Better training needed to reduce emergency caesareans
8. Better after-school snack choices boost nutrition for low-income kids, UC Davis research confirms
9. Outcomes of patients in trials; Better blood pressure treatment; Snake bites, and more
10. Better regulation needed for ethical research in Africa
11. Better procedures needed on care of prisoners in hospitals

Post Your Comments:
(Date:8/19/2014)... Horizon Blue Cross Blue Shield of New Jersey (Horizon BCBSNJ) ... up during The Barclays at The Ridgewood County Club ... Horizon BCBSNJ will be getting spectators into the walking fitness ... , Horizon BCBSNJ, the official health care sponsor of The ... the New Jersey Golf Foundation, an organization that removes barriers ...
(Date:8/19/2014)... Lupus and other rheumatic diseases can cause neurological ... delay a correct diagnosis for months, a new ... also cause these types of symptoms, according to ... Maywood, Ill. Rheumatic disorders include autoimmune and inflammatory ... as lupus, systemic vasculitis and ankylosing spondylitis. ...
(Date:8/19/2014)... August 19, 2014 Grande Naturals, ... the winner of the 2014 Independent Cosmetics Manufacturers ... the first place position in “Product Innovation; Product ... eyeliner, which also includes a lash enhancement serum, ... plus lash-boosting technology. , This all-new ...
(Date:8/19/2014)... Merrick, NY (PRWEB) August 19, 2014 In honor ... helping you care for your old furry friend by offering tips ... to rely on their owners more. Because of this, dog owners ... for them. , As dogs age, their needs change. They will ... outside as much as they used to. Because of this, pet ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 Following the completion ... Grand Hyatt Tampa Bay is proud to debut the ... second project included a full revamp of all public spaces ... guest rooms and suites, an all-new dining experience at 1823 ... hotel lobby. , With the introduction of 1823 Kitchen and ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 2Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 3Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 4Health News:Certain Symptoms Can Delay Lupus Diagnosis, Researchers Report 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 3Health News:The Puppy Store Helps Pet Owners Care for Aging Dogs 2Health News:Grand Hyatt Tampa Bay Hotel Unveils the Finishing Touches of Its $20 Million Makeover 2
(Date:8/19/2014)... 2014 According to a new ... Navigation Systems, ENT Navigation Systems and Orthopedic Navigation Systems) ... Forecast, 2014 - 2020", the global surgical navigation systems ... and is expected to grow at a CAGR of ... value of USD 295.5 million in 2020. ...
(Date:8/18/2014)... MARLBOROUGH, Mass. and NAGOYA, Japan ... Corporation (NYSE: BSX ) and ASAHI INTECC ... and Nagoya Stock Exchange) have formalized plans to ... The joint project focuses on creating a device intended ... The FFR market is an emerging field in ...
(Date:8/18/2014)... , Aug. 19, 2014 Immune Pharmaceuticals Inc. ... : "IMNP"), a biotechnology company, today announced that it ... stock on the NASDAQ Capital Market has been approved by ... Group. IMMUNE,s common stock is expected to begin trading on ... August 21, 2014 under the symbol IMNP. "We ...
Breaking Medicine Technology:Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 2Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 3Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 4Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 5Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 6Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 7Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 8Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 9Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 2Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 3Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 4Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 2Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 3Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 4
Cached News: